Evidence map›Paper›PMID 36158652›Full record

ArticleFrontiers in oncology2022

Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach.

Alessandra Fabi, Giuseppe Buono, Emilio Bria, Giampaolo Bianchini, Giuseppe Curigliano, Michelino De Laurentiis, Sabino De Placido, Lucia Del Mastro, Valentina Guarneri, Daniele Generali and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Alessandra FabiPrecision Medicine in Breast Cancer Unit, Scientific Directorate, Department of Woman and Child Health and Public Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Giuseppe BuonoDepartment of Breast and Thoracic Oncology, National Cancer Institute, IRCCS Fondazione G Pascale, Naples, Italy.
Emilio BriaComprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
Giampaolo BianchiniDepartment of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
Giuseppe CuriglianoDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Michelino De LaurentiisDepartment of Breast and Thoracic Oncology, National Cancer Institute, IRCCS Fondazione G Pascale, Naples, Italy.
Sabino De PlacidoDepartment of Clinical Medicine and Surgery, Oncology Division, University of Naples "Federico II", Naples, Italy.
Lucia Del MastroDepartment of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy.
Valentina GuarneriDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Istituto Oncologico Veneto (IOV) IRCCS, Padova, Italy.
Daniele GeneraliDepartment of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
Lorenzo LiviDepartment of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence, Florence, Italy.
Vito LorussoUnitá Operativa Complessa (U.O.C) Medical Oncology, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Filippo MontemurroBreast Surgery Strategic Program, Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (Piedmont Foundation for Oncology) - IRCCS, Torino, Italy.
Fabio PuglisiDepartment of Medical Oncology, Unit of Medical Oncology and Cancer Prevention, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
Paolo VigneriDepartment of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Alberto ZambelliDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
Grazia ArpinoDepartment of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment of HR+/HER2- metastatic breast cancer with cyclin-dependent kinases 4 and 6 inhibitors combined with endocrine therapy has recently emerged as the most relevant therapeutic strategy. However, in routine clinical practice, the best therapeutic approach in patients with comorbidities at early relapsing or

Indexed as

CDK4/6iconsensusDelphi surveymetastatic HR+/HER2-breast canceroncology

Identifiers

PMID36158652
PMCPMC9501706

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.